Peptide PT-141 (10mg) OxyPharma

Catalogue entry: Peptide PT-141 (10mg) OxyPharma. Labelled content: 10 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

PT-141 is the research designation commonly associated with bremelanotide, a melanocortin-receptor agonist. It belongs to a different signalling system from gonadorelin and reproductive pituitary hormones. Its relationship to Melanotan II concerns melanocortin pharmacology, not equivalent effects, formulations or authorisations.

What the research measured

Kingsberg and colleagues reported the RECONNECT phase III trials in Obstetrics and Gynecology in 2019. These studies concerned a defined sexual-desire disorder in a specific clinical population. Rosen and colleagues had earlier studied PT-141 in men. Neither setting establishes improved sporting performance, a general libido benefit for everyone or correction of exercise-related hormonal disturbances.

Sporting claims and limitations

Product-specific prescribing information for bremelanotide identifies important adverse effects and precautions, including nausea, blood-pressure effects and pigmentation changes. Those documents should not be shortened into a claim that a supplier preparation is safe. Clinical benefit and risk depend on diagnosis, formulation and the individual treatment context.

Product identity and documentation

The selected option records labelled content rather than a sexual-health treatment protocol. Assess the actual material's identity, chemical form, manufacturer reference and lot-specific tests separately. An approval of a named medicine in one jurisdiction is not approval of every PT-141-labelled product or permission to supply it across Europe. A research name on the label cannot establish pharmaceutical equivalence or resolve differences between the product and studied formulations.